Approval · Notice of Compliance 20112 · 2017

ABILIFY: Notice of Compliance 20112

Issued December 1, 2017

A Notice of Compliance is Health Canada’s approval of a drug submission: a new drug, a new use or form, or a change to an approved one. The product itself is in the Drug Product Database, with its current status.

Notice number: 20112
Date: December 1, 2017
Company: Otsuka Pharmaceutical Co LtdChiyoda-Ku Tokyo, --, Japan
Product type: Prescription Pharmaceutical
Submission: New Drug Submission (NDS)
Submission class: Labelling Only

Products in this notice

Brand	DIN	Status today
ABILIFY	02322374	Marketed
ABILIFY	02322382	Marketed
ABILIFY	02322390	Marketed
ABILIFY	02322404	Marketed
ABILIFY	02322412	Marketed
ABILIFY	02322455	Marketed

Medicinal ingredients

ARIPIPRAZOLE 2 MG per TAB
ARIPIPRAZOLE 5 MG per TAB
ARIPIPRAZOLE 10 MG per TAB
ARIPIPRAZOLE 15 MG per TAB
ARIPIPRAZOLE 20 MG per TAB
ARIPIPRAZOLE 30 MG per TAB